Business Context and Reporting Period
Company: Moderna, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 19, 2025
Event: Entry into a Material Definitive Agreement (Credit and Guaranty Agreement).
Key Financial Metrics and Debt Structure
This filing details a new credit facility rather than operational financial results. Key terms include:
- Total Facility Size: $1,500,000,000.
- Initial Funding: $600,000,000 funded as an initial term loan.
- Delayed Draw Term Loans: $900,000,000 available in two tranches:
- $400,000,000 available until November 2027.
- $500,000,000 available until November 2028, contingent on achieving key regulatory milestones for late-stage clinical pipeline.
- Interest Rates: Term SOFR + 5.50% or Base Rate + 4.50%.
- Maturity Date: November 24, 2030.
- Collateral: Secured by an all-asset collateral grant; guaranteed by U.S., Canadian, U.K., Swiss, and Australian subsidiaries.
Material Changes and Covenants
The filing introduces a new financial covenant requiring minimum liquidity levels:
- Minimum Liquidity Requirement: At least $500,000,000 in cash and cash equivalents on the last business day of each week.
- Increased Requirement: Rises to $750,000,000 if over $1,000,000,000 is drawn under the agreement.
- Waiver Condition: The covenant is not tested if the trailing 30-day average market capitalization exceeds $5,000,000,000.
- Cure Provision: Subject to a customary equity cure.
Note: This filing does not provide revenue, profit, or cash flow data for the period, nor does it compare these metrics to prior periods.
Guidance, Outlook, and Risks
Outlook and Milestones: Access to the final $500,000,000 tranche of the credit facility is explicitly contingent on the achievement of key regulatory milestones aligned with the Company's late-stage clinical pipeline.
Risks and Contingencies:
- Liquidity Risk: Failure to maintain the minimum cash balance (unless market cap waiver applies) constitutes an event of default.
- Operational Risk: Inability to meet regulatory milestones will prevent access to the full $1.5 billion facility.
- Debt Service: Interest rates are variable based on Term SOFR or Base Rate.
Investor Verification Checklist
- Verify current cash and cash equivalents to ensure compliance with the $500 million weekly minimum liquidity covenant.
- Confirm the current trailing 30-day average market capitalization to determine if the liquidity covenant is waived.
- Review the status of late-stage clinical pipeline programs to assess the likelihood of unlocking the $500 million milestone-contingent tranche.
- Examine the full text of the Credit Agreement (Exhibit 10.1) for specific definitions of "cash equivalents" and "regulatory milestones."
